**Abstract**

In our previous study, we reported that repeated stress (RS) of forced gastric insertion in ovariectomized (OVX) mice induced less attention, impaired cognition associated with GABAergic functional deficit via the expression alterations of K^+^-Cl^-^ co-transporter 2 (KCC2) and Na^+^-K^+^-2Cl ^-^co-transporter 1 (NKCC1) in the hippocampus. In this study, we aimed to investigate the effect of 17alfa-estradiol (alfaE2) as an anti-psychotic medicine and the involvement of G-protein-coupled estrogen receptor (GPR30) using immunohistochemical and behavioral analysis. 8-week-old C57/BL6J mice were OVX and/or RS were conducted for 21 days followed by several behavior tests. We found that GPR30 were overexpressed in the hippocampus of RS-OVX mice. Therefore, to prevent the overexpression of GPR30, we administered alfaE2 and G1, a GPR30 agonist, in RS-OVX mice. The administration prevented all the behavioral abnormalities and the expression alteration of KCC2, NKCC1 and GPR30. Additionaly, the efficacy of alfaE2 was completely diminished by co-administration of G15, an antagonist of GPR30. Subsequently, we evaluated the expressions of phosphorylated STE20- related proline/alanine--rich kinase (pSPAK) and oxidative stress response kinase-1 (pOSR1), a master regulator of KCC2 and NKCC1 activity. The perisomatic expression of pSPAK/pOSR1 altered correspondingly to that of KCC2 and NKCC1. Finally, we administered diazepam, a GABA~A~-Receptor agonist, to RS-OVX mice with vehicle, alfaE2 and G1 to confirm the normalization of behavior, KCC2, NKCC1 and GPR30 expression prevents the GABAergic dysfunction. Indeed, diazepam showed anxiolytic and anti-depression-like behavior in alfaE2 and G1 group, but not in vehicle treated group. In summary, alfaE2 mimicked the effect of GPR30 agonist and the effect of alfaE2 were completely diminished by G15, indicating that alfaE2 effect directly or deeply involved in the signal pathway of GPR30. We also found that alfaE2 regulate KCC2/NKCC1 activity via SPAK/OSRI. Thus, we propose alfaE2 as a promising medicine for treatment of neuropsychiatric diseases in postmenopausal women.
